The amyloid PET agent F-18 flutemetamol (Vizamyl) was the topic of two scientific sessions at the Alzheimer’s Association International Conference (AAIC), which concluded yesterday in Copenhagen. Results of one study showed improvements in clinical decision making and clinician confidence as a result of information gleaned from flutemetamol PET. In another study, patients with mild cognitive impairment (MCI) whose scans were positive for flutemetamol were 2.5 times more likely to progress to Alzheimer's disease.

IBA announced this week that the FDA has provided marketing authorization for the gantry beam line designed for the company’s compact proton therapy system, which will be used much like its larger cousins for the treatment of a variety of cancers.

NorthStar Medical Radioisotopes announced July 16 that the company had broken ground on the 50,000-square-foot production facility and headquarters in Beloit, Wis.

A cutting-edge detector developed by researchers in the United Kingdom and South Africa stands to spark more effective proton therapy for cancer patients.

First-in-human study of an investigational radiotracer, F-18 LMI1195, shows clear imaging of myocardial innervation via the norepinephrine transporter system—tipping off potential adverse cardiac events, according to a study published July 3 in the Journal of Nuclear Medicine.

New cases of dementia are diminished in developed nations, which could be a sign of the successes of preventative care and reduced risk factors. On the other hand, dementia may have been sorely underestimated in countries with lower and middle incomes, according to research presented during the current Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.

A number of factors are standing out as promoters for and protectors against the development of Alzheimer’s disease, according to research presented during the 2014 Alzheimer’s Association International Conference (AAIC) being held July 12-17 at the Bella Center in Copenhagen, Denmark.

Amino-acid biomarkers have undergone an evolution in the imaging of gliomas. Several agents have shown to be particularly useful, most notably C-11 MET, F-18 FDOPA, FLT and FET, according to a review of amino-acid imaging published July 8 in the Journal of Nuclear Medicine.